NDAC Meeting On Actual-Use Trials Scheduled For September
This article was originally published in The Tan Sheet
Executive Summary
FDA's Nonprescription Drugs Advisory Committee will convene Sept. 25 to "consider issues related to the analysis and interpretation of consumer behavior studies conducted to support marketing" of OTCs